The investigation specifically examines whether ADMA leadership prioritized short-term financial optics over fiduciary obligations amid signs of weakening demand for its intravenous immune globulin therapy. By allegedly pushing excess inventory into the distribution chain—a practice known as channel-stuffing—the board faces scrutiny regarding the transparency of its revenue reporting and overall governance standards.

ADMA, which operates out of Ramsey, New Jersey, specializes in biologics for immune deficiencies and infectious diseases. Investors seeking to participate in the inquiry or review their legal standing are directed to contact Andrew Abramowitz at 215-875-3015 or Caitlin Adorni at 267-764-4865. The firm, a veteran of complex class action litigation, is currently evaluating whether these practices caused material harm to shareholder value.